We are evaluating a new treatment for people with gastrointestinal cancers to see if it is safe and effective. This study aims to understand how well it works compared to existing options.
We are studying whether Guselkumab can help reduce inflammation in patients with psoriatic arthritis who have not received prior treatments. This trial focuses on those with ultrasound-confirmed enthesitis.
We are studying whether bevacizumab is more effective than corticosteroids for treating symptoms of cerebral radiation necrosis in patients with high-grade glioma or brain metastases. The trial also looks at quality of life and other health impacts.
We are studying whether stopping immunosuppressive therapy helps patients with ANCA vasculitis and end-stage renal disease avoid serious health issues compared to continuing treatment.
We are investigating whether adding ketamine to a therapy for chronic depression can reduce symptoms more effectively than a placebo. This study aims to help improve treatment options for those struggling with depression.
We are studying the long-term safety and effectiveness of CRISPR CAR cellular therapies in patients with hematological and solid malignancies. This research aims to provide insights into how well this treatment works over time.
We are studying the effects of three innovative treatments for pancreatic cancer to see if they improve quality of life and survival. This includes assessing pain levels and weight loss in patients.
We are exploring whether a new MRI technique can help detect small liver tumors earlier in people at risk for hepatocellular carcinoma. This may improve early diagnosis and treatment options.
We are investigating how advanced MRI can detect metabolic changes in patients with chronic kidney disease and polycystic kidney disease. This research may help improve diagnosis and treatment monitoring.
We are investigating the safety of a new treatment for patients receiving cochlear implants. This study aims to see if it can reduce surgery-related trauma and improve hearing outcomes.
We are studying the effects of Dostarlimab in patients with untreated Stage III colon cancer. This trial aims to understand how well the treatment works and its safety before surgery.
We are investigating whether adding Rituximab to IVIg treatment can help people with CIDP achieve long-term remission. This may reduce the need for regular infusions and associated healthcare costs.
We are studying the safety and effects of NECVAX-NEO1 added to standard PD-1 inhibitor therapy for patients with triple-negative breast cancer. This trial aims to see if the new treatment can enhance cancer response and improve outcomes.
We are comparing the effects of induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone for patients with locally recurrent rectal cancer. This study aims to see which approach leads to better surgical outcomes and survival rates.
We are studying whether Botox injections into the upper esophageal sphincter can help people who struggle to belch. This trial compares the effects of Botox with a placebo to assess symptom improvement.
We are investigating whether combining ketamine with electroconvulsive therapy helps people with treatment-resistant depression. The study also examines its effects on brain chemicals and cognitive function.
We are studying the effects of erdafitinib alone and with cetrelimab in patients with muscle-invasive bladder cancer who cannot take cisplatin. The goal is to see if this treatment can shrink tumors before surgery.
We are comparing a new treatment combining rilvegostomig with other medications to standard therapies for patients with HER2-positive gastric cancer. The goal is to see if this new approach improves survival and reduces disease progression.
We are studying whether GTX-102 can improve cognitive function and other skills in children with deletion-type Angelman Syndrome. The trial also aims to evaluate the safety of this new treatment.
We are comparing a new PET/CT imaging method with a standard test to see which better identifies adrenal tumors in patients with primary aldosteronism. This may help improve treatment for hypertension linked to this condition.